Explainer

What "compounded" actually means

Not a knock-off, not an approved drug. A specific legal category with specific consequences — explained without the scare tactics or the sales pitch.

Updated 2026-09-18

Disclosure: one company on this page — Coreage Rx — pays us a commission when a reader signs up through our link. It does not buy a better score, a higher ranking, or the removal of any criticism. The scoring rubric and the full disclosure are both published.

If you are paying under $300 a month for a GLP-1, you are almost certainly buying a compounded preparation. Here is precisely what that word means, without the scare stories and without the sales pitch.

Compounding is a licensed pharmacy preparing a medication for a patient, rather than a manufacturer producing it at scale. It is long-established and legal, and it exists to solve real problems — a patient who needs a dose that is not commercially made, or who cannot tolerate an ingredient in the standard product.

What it is not

Not counterfeit. A compounded preparation from a licensed pharmacy is a legitimate product, not a fake.
Not a generic. Generics are approved copies of approved drugs, reviewed by the FDA for equivalence. There is no approved generic semaglutide or tirzepatide.
Not FDA-approved. This is the crucial one. The agency has not reviewed the preparation for safety, effectiveness or manufacturing quality.
Not necessarily identical to the branded product. Concentration, excipients and stability can differ between pharmacies.

Why it became so common for GLP-1s

During the 2023–24 shortages, federal rules allowed compounding pharmacies to prepare copies of drugs on the FDA shortage list. Demand for semaglutide and tirzepatide vastly exceeded supply, and an entire telehealth industry grew up around that exemption.

What changed

When	What happened
December 2024	FDA declared the tirzepatide shortage resolved.
February 2025	FDA declared the semaglutide shortage resolved, ending the shortage-based pathway that allowed large-scale compounding.
16 September 2025	FDA issued more than 55 warning letters to online sellers of compounded GLP-1 medications.
1 April 2026	FDA reminded compounders that specific conditions must be met for compounded drugs to qualify for exemptions under sections 503A and 503B.
30 April 2026	FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List, saying there is no clinical need for compounded versions.
30 July 2026	Comment period on that proposal closed after an extension.
December 2025	FDA approved the first oral GLP-1 for weight management, the Wegovy pill, which launched in the US on 5 January 2026 from $149/month.
1 April 2026	FDA approved Foundayo (orforglipron), the first oral small-molecule GLP-1 for weight management, with self-pay from $149/month.
6 May 2026	CMS announced the Medicare GLP-1 Bridge, giving eligible Part D beneficiaries certain GLP-1s for $50 a month from 1 July 2026 through 31 December 2027.

Where that leaves things now

A 503A pharmacy may still compound a GLP-1 for an individual patient when there is a documented, patient-specific clinical reason — for example a required dose or formulation that the approved product does not provide.
Routinely marketed, off-the-shelf compounded GLP-1 sold like a consumer product is not permitted under that framework.
If the 503B Bulks List proposal is finalised, outsourcing facilities would lose the pathway they have been using to produce these drugs in volume.
Compounded versions are not FDA-approved. The agency does not review them for safety, effectiveness or manufacturing quality the way it reviews Zepbound or Wegovy.
The price argument for compounding is much weaker than it was. Two FDA-approved oral GLP-1s now start at $149 a month, and eligible Medicare beneficiaries can access certain GLP-1s for $50 a month from July 2026 — both below what many compounded programmes charge.

Important. If a seller does not require a prescription and a clinician review, that is not a bargain — it is a warning sign. The FDA issued more than 55 warning letters to online sellers of compounded GLP-1s in September 2025.

Questions worth asking before you buy

Which pharmacy fills this, and is it a 503A or 503B facility? (See 503A vs 503B.)
What is the patient-specific clinical reason for compounding in my case?
What concentration is it, and how should I store it?
What happens to my prescription — and any prepaid months — if the rules change again?
Can you transfer me to an FDA-approved product without restarting treatment?

If you would rather not have the question at all

Through LillyDirect self-pay, single-dose Zepbound vials at 5 mg, 7.5 mg and 10 mg have been listed at $499/month, with lower starting doses nearer $299-$349. Through NovoCare, Wegovy has been offered at $199/month for the first two fills through 31 December 2026, then $349/month for 0.25-2.4 mg doses. The oral form is listed between $149 and $299/month by dose. Ro dispenses only approved products. We compare the two routes in brand-name vs compounded.